<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02726139</url>
  </required_header>
  <id_info>
    <org_study_id>BVARI_GG_2016_1</org_study_id>
    <nct_id>NCT02726139</nct_id>
  </id_info>
  <brief_title>Improved Factor VIII Inhibitor Evaluation</brief_title>
  <acronym>IFIE</acronym>
  <official_title>Improved Factor VIII Inhibitor Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston VA Research Institute, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston VA Research Institute, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Commercial one and two-stage factor VIII assays may not detect some clinically significant&#xD;
      inhibitor antibodies. The purpose of the proposed study is to standardize and validate a&#xD;
      platelet-based factor VIII activity assay with greater sensitivity to clinically important&#xD;
      inhibitory antibodies. Investigators will evaluate the platelet-dependent inhibitory activity&#xD;
      vs. conventional inhibitory activity in stored patient plasmas and correlate to bleeding&#xD;
      histories&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Factor VIII activity assays are used to diagnose hemophilia A, to monitor treatment of these&#xD;
      patients, to determine when inhibitory antibodies against factor VIII have developed, and to&#xD;
      evaluate the activity of engineered pharmaceutical factor VIII products. Factor VIII activity&#xD;
      has been measured with one and two-stage assays for more than fifty years. However, all&#xD;
      existing assays have major shortcomings that are recognized by the FDA, the International&#xD;
      Society for Thrombosis and Haemostasis, and pharmaceutical companies. The major deficiencies&#xD;
      that have been identified are: 1) Factor VIII activity levels do not predict the risk of&#xD;
      bleeding in patients with inhibitory antibodies. The degree of inhibition in these assays is&#xD;
      less than required to explain patient bleeding. 2) The assays are only accurate over a range&#xD;
      of 1 - 100% of normal factor VIII activity, while values of 0.1 - 1% are also clinically&#xD;
      important. 3) The different approved assays give discrepant values for recombinant&#xD;
      pharmaceutical factor VIII products, with a range of 2-fold difference between assays. This&#xD;
      can lead to clinically important differences in dosing of factor VIII products from one&#xD;
      region to another with corresponding risk of thrombosis or bleeding.&#xD;
&#xD;
      The preliminary data identify an additional deficiency of commercial assays that has not been&#xD;
      anticipated. Commercial one and two-stage assays may not detect some clinically significant&#xD;
      inhibitor antibodies. Thus, the purpose of the proposed studies is to standardize and&#xD;
      validate a platelet-based factor VIII activity assay with greater sensitivity to clinically&#xD;
      important inhibitory antibodies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No participants enrolled&#xD;
  </why_stopped>
  <start_date type="Actual">July 15, 2016</start_date>
  <completion_date type="Actual">January 25, 2021</completion_date>
  <primary_completion_date type="Actual">January 25, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding exceeds risk predicted by factor VIII assay</measure>
    <time_frame>1 year</time_frame>
    <description>annual bleeding rate exceeds the rate predicted from the residual factor VIII activity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding is in accord with the risk assigned by platelet-dependent factor VIII activity</measure>
    <time_frame>1 year</time_frame>
    <description>annual bleeding rate is within the predicted range from residual factor VIII activity</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Hemophilia</condition>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Emory University</arm_group_label>
    <description>Samples obtained at and shipped from Emory University</description>
  </arm_group>
  <arm_group>
    <arm_group_label>University of Michigan</arm_group_label>
    <description>Samples obtained at and shipped from University of Michigan</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      frozen plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with hemophilia A and inhibitory antibodies that have agreed to store plasma and&#xD;
        prospectively consented to testing to evaluate bleeding mechanism&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  hemophilia A&#xD;
&#xD;
          -  presence of inhibitory antibodies&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Boston VA Research Institute (BVARI)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>March 29, 2016</study_first_submitted>
  <study_first_submitted_qc>March 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2016</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Factor VIII</keyword>
  <keyword>inhibitor</keyword>
  <keyword>assay</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

